S-1/A: Glucotrack Seeks to Raise Capital Through Offering of Common Stock and Warrants

Glucotrack, Inc. is offering shares of common stock along with Series A and Series B warrants, and pre-funded warrants, aiming to raise capital for general corporate purposes, including clinical trials and operating expenses.

Summary

• Glucotrack, Inc., a medical device company focused on developing an implantable continuous glucose monitor (CBGM), has filed an amendment to its Form S-1 registration statement with the SEC.
• The company is offering up to a specified number of shares of common stock, along with Series A and Series B common warrants.
• Pre-funded warrants are also being offered as an alternative to common stock for purchasers who might exceed ownership thresholds.
• Each share of common stock or pre-funded warrant is sold together with Series A and Series B common warrants.
• The company has engaged Dawson James Securities, Inc. as the exclusive placement agent for the offering.
• The offering will terminate on a specified date in 2024, unless terminated earlier by the company.
• The company intends to use the net proceeds from this offering for general corporate purposes, including operating expenses, clinical trial expenses, and working capital.
• Glucotrack is a smaller reporting company and is subject to reduced public company reporting requirements.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol GCTK.
• The company completed a preclinical study demonstrating the feasibility of glucose monitoring in the epidural space.
• A reverse stock split of 1-for-5 was effected on May 17, 2024.
• The company received an extension from Nasdaq until November 18, 2024, to regain compliance with the minimum stockholders' equity requirement.

Sentiment

Score: 4

Explanation: The document highlights both positive developments (successful preclinical studies, Nasdaq extension) and significant risks (going concern warning, potential dilution, reliance on third-party manufacturers). The capital raise itself is a necessity, not necessarily a positive, given the company's financial situation.

Positives

• The company has completed a preclinical study demonstrating the feasibility of glucose monitoring in the epidural space.
• The company has initiated a longer-term animal trial and development of its commercial device.
• A regulatory submission has been made for a first in human study, expected to initiate in Q3 2024.
• The company received an extension from Nasdaq until November 18, 2024, to regain compliance with the minimum stockholders' equity requirement.

Negatives

• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received.
• The company's independent registered public accounting firms report contains an explanatory paragraph that expresses substantial doubt about the company's ability to continue as a going concern.
• The company has debt which is secured by all its assets, and if there is an uncured event of default, the lender can foreclose on all the assets.
• The company relies on third parties to manufacture and supply its product.

Risks

• The offering is on a best efforts basis, and the company may not raise the amount of capital required.
• Management has broad discretion in how the proceeds from the offering are used.
• The price of the company's common stock may fluctuate significantly.
• The company does not anticipate paying dividends in the foreseeable future.
• Investors may incur immediate and substantial dilution in the book value of their shares.
• The company's reverse stock split may decrease the liquidity of the shares of its common stock.
• The company may not be able to achieve profitability going forward and may not be able to raise additional capital necessary to continue as a going concern.
• The company's failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of its common stock.
• The company relies on third parties to manufacture and supply its product.

Future Outlook

The company intends to use the net proceeds from this offering for general corporate purposes, which may include operating expenses, clinical trial expenses and working capital.

Industry Context

The company is operating in the medical device industry, specifically focusing on continuous glucose monitoring (CGM) for diabetes patients, a market with established players like DexCom and Medtronic.

Comparison to Industry Standards

• Glucotrack is developing an implantable CGM, similar to Senseonics' Eversense, but aims for longer implant longevity.
• DexCom and Abbott are leaders in the CGM market with non-implantable sensors, while Glucotrack is pursuing an implantable solution.
• The company's epidural glucose sensing approach is novel and could potentially address a specific need for patients with painful diabetic neuropathy.

Stakeholder Impact

• Shareholders face potential dilution and the risk of stock price volatility.
• Employees' job security is tied to the company's ability to raise capital and achieve profitability.
• Customers (diabetes patients) could benefit from the successful development of the CBGM product.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• Initiate a first in human study, expected in Q3 2024.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement by November 18, 2024.
• Continue development of the commercial device.
• Seek Stockholder Approval for the July 30 Note within 90 days.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, offering, Glucotrack, CBGM, Nasdaq, capital raise, glucose monitor, medical device